Natco Pharma is a complex generic drug manufacturer with a diversified footprint across India, the US, Brazil, Canada and a 49% economic interest in South Africa's Adcock Ingram. Its portfolio includes oncology, GLP-1 products and a crop health sciences division. Historically, earnings were highly concentrated in a single product, Revlimid, which has now fallen to negligible levels; the base business (excluding Revlimid) is growing double digits, with domestic formulations revenue at ₹136 crore in Q1 FY27 and Brazil revenue up 180% to ₹178 crore. EBITDA margin was 30.9% including other income in Q1 FY27, but that reflects a mix of high-margin specialty and commodity like generics; the company faces intense competition in many molecules.
The economics persist because of the high barriers in complex generics: Para-IV litigation, first-to-file exclusivities and regulatory approval cycles. Natco holds sole or shared FTF status on several products, including semaglutide in the US, and has a pipeline of exclusivity launches between 2026 and 2035. Its four FDA-inspected plants provide a foundation for regulatory approvals, and the warning letter on the Kothur facility was lifted in 2025, enabling more supply. The company's 49% stake in Adcock adds distribution and a stable earnings base of roughly ₹100 crore per quarter, after adjusting for flu season spikes. This diversification reduces the cyclicality of the US generics market, though the semaglutide market in India is intensely competitive with 10-15 generic players.
The inflection is now. FY27 revenue guidance is INR3,400-3,500 crore with PAT of INR700-750 crore, down from FY26's ~INR4,300 crore as Revlimid disappears, but the base is reshaped. By the second half of calendar 2027, Carfilzomib is expected to launch in the US after a plant upgrade is completed by end of 2026, and a shared FTF launch is expected in the next fiscal year. The domestic business is targeting 25% growth this year, led by semaglutide (currently ~₹2 crore per month) which is expected to reach annualized sales of INR75-100 crore once pricing stabilizes. Brazil and Canada subsidiaries are scaling from a base of INR730 crore, and crop health sciences is guided to break even this year with around ₹140-150 crore revenue before a demerger expected around October 2026. By 18-24 months out, the company expects earnings to compound 15-25% annually starting FY28, driven by US exclusivity launches and Adcock's steady contribution.
Management's walk-talk has been mixed. They guided FY26 revenue and PAT of INR4,300 crore and INR1,300 crore, which were met, but they promised R&D moderation and cost declines that did not materialize; R&D remained high and other expenses stayed elevated. Launch timelines for semaglutide, pomalidomide and risdiplam slipped repeatedly. In Aug 2026, they raised INR2,000 crore via a fundraise for acquisitions and short-term loan repayment, and spent ~INR3,000 crore over the last year on two stake acquisitions in Adcock, lifting to 49%. They have no buyback plan and hold net cash of ~INR1,400 crore after these moves. The demerger of crop health sciences was delayed by 2-3 months due to fundraising, now expected around October 2026, and they aim to close at least one acquisition in calendar 2026.
Earnings visibility is moderate. The PAT path for FY27 is INR700-750 crore, with Adcock alone contributing roughly INR400 crore (based on ~₹100 crore per quarter), domestic and international base business providing the rest. For FY28, the compound growth of 15-25% hinges on successful launches of Carfilzomib and other FTF products in the US, continued growth in Brazil and Canada, and pricing stability in semaglutide. The kill shot is execution: if launch dates slip again or if the Adcock integration fails to yield pipeline synergies, the base growth will fall short. Also, the acquisition spree could dilute returns if deals overpay. The single most important watchpoint is the timeline for US launches and the resolution of Olaparib litigation, which has a trial date within the next few months. If that fails, the exclusivity upside vanishes.
companyname: Natco Pharma Limited ticker: NATCOPHARM sector: Pharmaceuticals Natco Pharma is a vertically integrated generic drug manufacturer founded in Hyderabad in 1981. The core of the strategy is complex generics - oncology above all - paired with early patent challenges (Paragraph IV filings) that win temporary first-to-file exclusivity in the US market, creating monopoly windows with outsize margins before the wave of competitors arrives. In FY25, that model produced consolidated revenu...
Read the full report →geographic expansion, acquisition inorganic
FY27 revenue guided at INr3,400-3,500 crores with PAT of inr700-750 crores driven by diversified revenue from India, US, Brazil, Canada, and South African associate performance
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Natco Pharma Limited and 4,900+ companies.
5-day free pass. No card required.